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Southall made several points about our recent article.1 2
He suggests that “lethal hyperchloraemia” secondary to use of
normal saline in FEAST (for boluses or maintenance) resulted
in excess mortality. However, he did not comment on the key
finding of the trial—that the increased 48 hour mortality was
identical in both normal saline bolus (10.6%) and albumin bolus
(10.6%) arms compared with the no bolus control group (7.3%).3
Harm was shown for every age group, in every condition, at
each of the six hospitals, regardless of degree of acidosis,4 and
for all definitions of shock.5 Despite differences in physical
properties of albumin and saline, the timing of excess mortality
after administration was identical (Kaplan-Meier mortality
curves),3 making his hypothesis improbable.
With regard tomaintenance fluids, use in the trial was pragmatic,
given either as part of a quinine infusion (World Health
Organization recommends 5% dextrose) or the local “standard
of care” maintenance fluid, and stopped as soon as the child
could retain oral fluids. The median volume of maintenance
fluid received over 48 hours was 50 mL/kg (interquartile range
35.3-60) alongside quinine infusion or 51.8 mL/kg (26.1-83.2)
as maintenance. The chief maintenance fluid was 5% dextrose
(Uganda), 5% dextrose/0.9% saline (Teule), or 5%
dextrose/0.45% saline (Kilifi). Data on fluid volumes are already
in the public domain, published alongside the New England
Journal of Medicinemanuscript (table 3a supplementary files).3
Details of the diagnoses of the deaths by arm are listed in
supplementary files (table 2b: Endpoint review committee
adjudication of deaths).
Finally, Southall indicates that all children in the FEAST trial
were exposed to harm (whether from normal saline or hypotonic
5% dextrose), even though these are used widely across Africa.
However, global mortality in FEAST (all three arms) was
substantially better than predicted by previous studies, including
the quinine arm of the AQUAMATmalaria trial (10.9%)6 versus
FEAST malaria subgroup bolus arms (9.2%) and control
(5.7%).5
Most children in the bolus arms received only 20 mL/kg, lower
than is currently recommended byWHO and other international
guidelines. Even this relatively conservative volume of fluid
boluses resulted in harm, which is why we are calling forWHO
to reverse its liberal bolus guidance for febrile sick African
children with shock not caused by fluid loss. Current WHO
guidance is costly, difficult to implement (most African hospitals
cannot accurately measure fluid boluses), and unsupported by
evidence.
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